![](https://static.wixstatic.com/media/a1d97b_4da9de9631f2493abfb4e67682392bca~mv2.jpg/v1/fill/w_288,h_144,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/a1d97b_4da9de9631f2493abfb4e67682392bca~mv2.jpg)
![](https://static.wixstatic.com/media/a1d97b_9b27bbd36ca64c60a933a337ffd6835b~mv2.png/v1/fill/w_219,h_79,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/a1d97b_9b27bbd36ca64c60a933a337ffd6835b~mv2.png)
Welcome to Future Island!
Speakers 2024
Neue Medikamente gegen Übergewicht. Experte dafür:
Matthias Tschöp
CEO, Helmholtz Munich; VP, Helmholtz Association; Alexander von Humboldt Professor, Technical University of Munich
Helmholtz Munich
Matthias Tschöp is the CEO of Helmholtz Munich, Vice President of the German Helmholtz Association and Alexander-von-Humboldt Professor at the Technical University of Munich. Tschöp unraveled fundamental gut-brain signals to discover the first highly effective drugs for human obesity in collaboration with the chemist Richard DiMarchi - the dual and triple gut hormone multi-agonists. A first representative is FDA-approved, others are successfully progressing through clinical trials. Tschöp has received numerous honors and awards, including the Banting Medal (2023), the Heinrich Wieland Prize (2023), the Schering Prize (2023), the EASD-Lilly Centennial Prize (2022) and the Ernst Jung Prize (2021). He holds an adjunct professorship at Yale University and an honorary doctorate at Leipzig University. He was elected a member of the German, Bavarian, and European Academies of Sciences, the American Society for Clinical Investigation and the Association of American Physicians.
Sessions:
![Matthias Tschöp](https://static.wixstatic.com/media/a1d97b_d72347b74dfe49ad86d25563712b9c05~mv2.png/v1/fill/w_392,h_392,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Image-empty-state.png)